VKTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Viking Therapeutics Inc (VKTX) is not a strong buy for a beginner, long-term investor at this moment. Despite positive developments in its drug pipeline and strong cash reserves, the company's financial performance remains weak, with significant losses and rising R&D expenses. Technical indicators and options data suggest a neutral to slightly bearish sentiment, and insider selling further dampens confidence. Holding the stock or waiting for clearer positive signals is recommended.
The MACD is positive and expanding, indicating a potential upward momentum. However, the RSI is neutral at 57.262, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Support is at 26.463, and resistance is at 33.041. The stock is currently trading at 30.32, slightly above the pivot level of 29.752, suggesting limited upside potential in the short term.
Strong demand for VK2735 following Novo Nordisk's launch of oral Wegovy.
Plans to start Phase 3 trials for VK2735 in Q3
Solid cash position of $706 million to support R&D and operational needs.
Significant insider selling, with a 206.50% increase in the last month.
Weak financial performance, with a Q4 loss of $1.38 per share and rising R&D expenses.
Lack of recent congress trading data or influential figure purchases.
In Q4 2025, Viking Therapeutics reported a net income loss of $157.66 million, an EPS of -1.38, and no revenue growth. While the YoY improvement in net income and EPS is notable, the company remains unprofitable, with high R&D expenses ($153.5 million).
Morgan Stanley analyst Michael Ulz maintains an Overweight rating but lowered the price target from $102 to $99, reflecting cautious optimism.
